Contents

Search

velagliflozin (Senvelgo)

Indications: - diabetes mellitus type 2 alone or with other agents in horses & ponies Dosage: - 0.3 mg/kg BW, PO once a day - 15 mg/mL oral solution

Interactions

drug adverse effects of hypoglycemic agents

General

SGLT-2 inhibitor; oral glucosuric agent; flozin

References

  1. Meier A, de Laat M, Reiche D et al The efficacy and safety of velagliflozin over 16 weeks as a treatment for insulin dysregulation in ponies. BMC Vet Res. 2019 Feb 26;15(1):65 PMID: 30808423 PMCID: PMC6390376 Free PMC article
  2. Meier A, Reiche D, de Laat M, Pollitt C, Walsh D, Sillence M. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13(9):e0203655. PMID: 30212530 PMCID: PMC6136744 Free PMC article